Zoetis (ZTS) ended the recent trading session at $182.42, demonstrating a +1.32% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 1.37%. Elsewhere, the Dow lost 1.21%, while the tech-heavy Nasdaq lost 2.3%.Prior to today's trading, shares of the animal health company had gained 2.53% over the past month. This has outpaced the Medical sector's gain of 0.74% and the S&P 500's gain of 1.11% in that time.The investment community will be closely monitorin ...

Wall Street analysts forecast that Zoetis (ZTS) will report quarterly earnings of $1.49 per share in its upcoming release, pointing to a year-over-year increase of 5.7%. It is anticipated that revenues will amount to $2.3 billion, exhibiting an increase of 5.6% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their i ...

The market expects Zoetis (ZTS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Augu ...

The most recent trading session ended with Zoetis (ZTS) standing at $179.84, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 1.11%. Elsewhere, the Dow gained 1.64%, while the tech-heavy Nasdaq added 1.03%.Coming into today, shares of the animal health company had gained 2.44% in the past month. In that same time, the Medical sector lost 0.54%, while the S&P 500 lost 1.16%.The investment community will be closely monitoring th ...

Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "Veterinary Pharmaceutical Manufacturing in Australia - Industry Market Research Report" report has been added to ResearchAndMarkets.com's offering.This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares. Veterinary pharmaceutical manufacturers have endured their ...

Vesnaandjic/E+ via Getty Images Zoetis (NYSE:ZTS) is a leading animal pharmaceutical company, primarily focused on both companion pets and livestock. Zoetis boasts a robust portfolio of long-lasting blockbusters, benefiting from lower R&D costs and quicker development timelines compared to human pharmaceuticals. However, valuation concerns persist amidst reliance on key drug launches for future growth. One-Minute Summary of Zoetis' Business Here are some key highlights of Zoetis' business and industry i ...

JHVEPhotoZoetis Is The Animal Healthcare Leader Zoetis Inc. (NYSE:ZTS) is a fundamentally strong healthcare company focusing primarily on animal health. Zoetis has a long history of delivering on its value proposition "by advancing care for animals." As a result, it has propelled ZTS into one of the world's leaders in animal health, capitalizing on its massive global scale and R&D expertise. Moreover, a relatively more fragmented market (as compared to the human health business) has also afforded Zoetis ...

JHVEPhoto Just over a year ago, I thought Zoetis Inc. (NYSE:ZTS), the undisputed leader in the animal health industry, was fairly valued even at premium valuation multiples given that the company enjoys durable competitive advantages stemming from its scale and brand recognition. Since then, Zoetis stock has gained just 2% while the S&P 500 has soared almost 30%. This underperformance, if continued for longer, may spook investors, but I believe long-term investors should double down on ZTS stock because ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On April 12, 2024, The Wall Street Jou ...

Zoetis (ZTS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this animal health company have returned +0.7% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Medical - Drugs industry, to which Zoetis belongs, has gained 0.1% over this period. Now the key question is: Where could the stock be headed in the near term?Although ...